Financials data is unavailable for this security.
Cash flow in CHFView more
In 2023, Altamira Therapeutics Ltd increased its cash reserves by 9,806.87%, or 485.44k. Cash Flow from Financing totalled 1.00m or 632.07% of revenues. In addition the company used 516.13k for operations while cash from investing totalled 2.07k.
Cash flow per share | -7.49 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.0746 |
---|---|
Tangible book value per share | -0.0746 |
More ▼
Balance sheet in CHFView more
Current ratio | 2.36 |
---|---|
Quick ratio | 1.79 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼